References
- Clinical Trial Transformation Initiative (CTTI) (2012), Antibacterial Drug Development: Statistical Issues Think Tank. Available at http://www.ctti-clinicaltrials.org/what-we-do/ctti-projects/unmet-need/expert-meetings/1.
- Clinical Trial Transformation Initiative (CTTI) (2014), Statistical Issues Think Tank II. Available at http://www.ctti-clinicaltrials.org/what-we-do/ctti-projects/unmet-need-antibiotic-development/expert-meetings/3.
- Engelberg Center for Health Care Reform at Brookings (2012), Facilitating Antibacterial Drug Development. Available at http://www.brookings.edu/events/2012/05/09-antibacterial-drug-development.
- Evans, S.R., Rubin, D., Follmann, D., Pennello, G., Huskins, W. C., Powers, J. H., Schoenfeld, D., Chuang-Stein, C., Cosgrove, S. E., Fowler, V. G., Lautenbach, E., and Chambers, H. F. (2015), “Desirability of Outcome Ranking (DOOR) and Response Adjusted for Days of Antibiotic Risk (RADAR),” Clinical Infectious Diseases, available at http://cid.oxfordjournals.org/content/early/2015/06/24/cid.civ495.
- Follmann, D., Brittain, E., and Powers, J.H. (2013), “Discordant Minimum Inhibitory Concentration Analysis: A New Path to Licensure for Anti-Infective Drugs,” Clinical Trials, 10, 876–85.
- Food and Drug Administration, Fast Track (2015), Breakthrough Therapy, Accelerated Approval, Priority Review. Available at http://www.fda.gov/ForPatients/Approvals/Fast/ucm20041766.htm.
- Food and Drug Administration (FDA) (2013), Guidance for Industry, Acute Bacterial Skin and Skin Structure Infections: Developing Drugs for Treatment. Available at http://www.fda.gov/downloads/Drugs/…/Guidances/ucm071185.pdf.
- Gamalo, M.A., Tiwari, R.C., and LaVange, L.M. (2014), “Bayesian Approach to the Design and Analysis of Non-Inferiority Trials for Anti-Infective Products,” Pharmaceutical Statistics, 13, 25–40.
- Hartzell, J.D., Neff, R., Ake, J., Howard, R., Olson, S., Paolino, K., Vishnepolsky, M., Weintrob, A., and Wortmann, G. (2009), “Nephrotoxicity Associated with Intravenous Colistin (Colistimethate Sodium) Treatment at a Tertiary Care Medical Center,” Clinical Infectious Diseases, 48,1724–1728.
- Huque, M.F., Valappil, T., and Soon, G.G. (2014), “Hierarchical Nested Trial Design (HNTD) for Demonstrating Treatment Efficacy of New Antibacterial Drugs in Patient Populations with Emerging Bacterial Resistance,” Statistics in Medicine, 33(25), 4321–36.
- Lux, L.J., Posey, R.E., Daniels, L.S.C. Henke, D.C., Durham, C., Jonas, D.E., and Lohr, K.N. (2014), “Pharmacokinetic/Pharmacodynamic Measures for Guiding Antibiotic Treatment for Hospital-Acquired Pneumonia,” Comparative Effectiveness Review, 136, 1–142.
- President's Council of Advisors on Science and Technology (2014), Report to the President on Combating Antibiotic Resistance. Avail-able at https://www.whitehouse.gov/sites/default/files/microsites/ostp/PCAST/pcast_carb_report_sept2014.pdf.
- The White House (2015), National Action Plan for Combating Antibiotic-Resistant Bacteria. Available at https://www.whitehouse.gov/sites/default/files/docs/national_action_plan_for_combating_antibotic-resistant_bacteria.pdf.
- United States Centers for Disease Control and Prevention (CDC) (2013), Antibiotic Resistance Threats in the United States. Available at http://www.cdc.gov/drugresistance/pdf/ar-threats-2013–508.pdf.
- World Health Organization (2014), Antimicrobial Resistance Global Report on Surveillance. Available at http://apps.who.int/iris/bitstream/10665/112642/1/9789241564748_eng.pdf.